Compare WBX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | DSGN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 528.1M |
| IPO Year | N/A | 2021 |
| Metric | WBX | DSGN |
|---|---|---|
| Price | $3.05 | $8.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.00 | ★ $13.50 |
| AVG Volume (30 Days) | 27.2K | ★ 298.9K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,593,453.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.85 | $2.60 |
| 52 Week High | $14.40 | $10.31 |
| Indicator | WBX | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 51.79 |
| Support Level | $2.88 | $9.00 |
| Resistance Level | $3.36 | $9.67 |
| Average True Range (ATR) | 0.27 | 0.65 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 13.77 | 15.64 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.